<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12473877
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     12
    </month>
    <day>
     10
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     06
    </month>
    <day>
     18
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0263-6352
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       20
      </volume>
      <issue>
       12
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of hypertension
     </title>
     <isoabbreviation>
      J. Hypertens.
     </isoabbreviation>
    </journal>
    <articletitle>
     Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.
    </articletitle>
    <pagination>
     <medlinepgn>
      2513-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the relative importance of recognised risk factors for non-haemorrhagic stroke, including serum cholesterol and the effect of cholesterol-lowering therapy, on the occurrence of non-haemorrhagic stroke in patients enrolled in the LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) study.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      The LIPID study was a placebo-controlled, double-blind trial of the efficacy on coronary heart disease mortality of pravastatin therapy over 6 years in 9014 patients with previous acute coronary syndromes and baseline total cholesterol of 4-7 mmol/l. Following identification of patients who had suffered non-haemorrhagic stroke, a pre-specified secondary end point, multivariate Cox regression was used to determine risk in the total population. Time-to-event analysis was used to determine the effect of pravastatin therapy on the rate of non-haemorrhagic stroke.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      There were 388 non-haemorrhagic strokes in 350 patients. Factors conferring risk of future non-haemorrhagic stroke were age, atrial fibrillation, prior stroke, diabetes, hypertension, systolic blood pressure, cigarette smoking, body mass index, male sex and creatinine clearance. Baseline lipids did not predict non-haemorrhagic stroke. Treatment with pravastatin reduced non-haemorrhagic stroke by 23% (P = 0.016) when considered alone, and 21% (P = 0.024) after adjustment for other risk factors.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The study confirmed the variety of risk factors for non-haemorrhagic stroke. From the risk predictors, a simple prognostic index was created for non-haemorrhagic stroke to identify a group of patients at high risk. Treatment with pravastatin resulted in significant additional benefit after allowance for risk factors.
     </abstracttext>
    </abstract>
    <affiliation>
     Prince Charles Hospital, Brisbane, Australia. malcolm.west@mailbox.uq.edu.au
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       West
      </lastname>
      <forename>
       Malcolm J
      </forename>
      <initials>
       MJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       White
      </lastname>
      <forename>
       Harvey D
      </forename>
      <initials>
       HD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Simes
      </lastname>
      <forename>
       R John
      </forename>
      <initials>
       RJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kirby
      </lastname>
      <forename>
       Adrienne
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Watson
      </lastname>
      <forename>
       John D
      </forename>
      <initials>
       JD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Anderson
      </lastname>
      <forename>
       Neil E
      </forename>
      <initials>
       NE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hankey
      </lastname>
      <forename>
       Graeme J
      </forename>
      <initials>
       GJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wonders
      </lastname>
      <forename>
       Susan
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hunt
      </lastname>
      <forename>
       David
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tonkin
      </lastname>
      <forename>
       Andrew M
      </forename>
      <initials>
       AM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     J Hypertens
    </medlineta>
    <nlmuniqueid>
     8306882
    </nlmuniqueid>
    <issnlinking>
     0263-6352
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticholesteremic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      81093-37-0
     </registrynumber>
     <nameofsubstance>
      Pravastatin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Hypertens. 2002 Dec;20(12):2359-62
     </refsource>
     <pmid version="1">
      12473858
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticholesteremic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Blood Pressure
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Coronary Disease
     </descriptorname>
     <qualifiername majortopicyn="Y">
      complications
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      mortality
     </qualifiername>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pravastatin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prognosis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Stroke
     </descriptorname>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      12
     </month>
     <day>
      11
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      6
     </month>
     <day>
      19
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      12
     </month>
     <day>
      11
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12473877
    </articleid>
    <articleid idtype="doi">
     10.1097/01.hjh.0000042890.24999.00
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

